Nordic Life Science
Latest news
Children who develop inflammatory bowel disease (ulcerative colitis or Crohn’s disease) run a higher risk of cancer, both in childhood and later in life, reports a study from Karolinska Institutet
BONESUPPORT announces that a pre-clinical study evaluating the in-vivo release kinetics of radio-labelled bone morphogenic protein (rhBMP-2) and zoledronic acid (ZA) from CERAMENT BONE VOID FILLER (BVF) was presented at
Essity and Microsoft will partner to leverage the power of big data and cloud computing to enhance Essity’s hygiene and health products and solutions. Essity will implement Microsoft’s Azure cloud-based
NLSDays 2017 took place in a windy and rainy Medicon Valley, but with a warm and collaborative atmosphere among its participants. This year’s Nordic Life Science Days, going on its fifth year,
Alligator Bioscience has signed a research collaboration agreement with Professor Ignacio Melero, MD, PhD, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain, to further investigate the biology of 4-1BB
For the fifth year, the Nordic Star Awards was presented at the end of the NLSDays conference, honoring three innovative life science companies in the Nordic region. Nordic Stars Awards
NLSDays 2017 started off with a super session with the title “Gene therapy in regenerative medicine” and both challenges and possibilities were discussed. Dr Sven Kili, Head of Cell and Gene
The company announces that a new method of use patent for the drug candidate cobitolimod has been granted by the Japan Patent Office. The patent provides additional protection for the
Sponsored Content
Drug development is a huge investment for small and large pharmaceutical companies, that is both lengthy and risky. Reducing time to market and increasing the chances of a drug’s success are essential for pharmaceutical companies
0 Views
Business
BONESUPPORT announces that a pre-clinical study evaluating the in-vivo release kinetics of radio-labelled bone morphogenic protein (rhBMP-2) and zoledronic acid (ZA) from CERAMENT BONE VOID FILLER (BVF) was presented at
In Focus – Oncology
The rapid development within nanotechnology drug delivery is creating new possibilities to treat common diseases and improving pharmaceuticals. Safety aspects and competitionwith established treatments are however some of the obstacles
618 Views
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology
725 Views
Liquid biopsies, sequencing and upgraded software tools are among some of the recent and ongoing trends in cancer diagnostics. Developments in the diagnostic sector have vastly improved the ability to
660 Views
Research
Children who develop inflammatory bowel disease (ulcerative colitis or Crohn’s disease) run a higher risk of cancer, both in childhood and later in life, reports a study from Karolinska Institutet
Innovative cabinet design and flexible shelf layout in the New TwinGuard ULT Upright Freezers 15 September 2017 by Panasonic
Step up sample security with the new TwinGuard Ultra Low Temperature Upright Freezers from Panasonic 12 September 2017 by Panasonic
Early business strategy to optimise a new drug’s product differentiation & chances of market success 5 September 2017 by PCG Clinical Services
The IncuSafe Advantage: a precise and regulated environment for your cell cultures 29 August 2017 by Panasonic
New Innovation and Design
BONESUPPORT announces that a pre-clinical study evaluating the in-vivo release kinetics of radio-labelled bone morphogenic protein (rhBMP-2) and zoledronic acid (ZA) from CERAMENT BONE VOID FILLER (BVF) was presented at
Clinical Trials
MedImmune, AstraZeneca’s global biologics R&D arm, have been informed by partner Celgene that the US Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a
Drug Development
NLSDays 2017 started off with a super session with the title “Gene therapy in regenerative medicine” and both challenges and possibilities were discussed. Dr Sven Kili, Head of Cell and Gene
Careers – On A New Job
Dr Paula Salmikangas, former chair of EMA Committee for Advanced Therapies (CAT), has joined the NDA Advisory Board as Director of
SwedenBIO has appointed Helena Strigård as deputy CEO and Head of Policy. The national non-profit association for the life science
Teva Pharmaceutical Industries has announced that its Board of Directors has named Kåre Schultz to become the company’s President and
AstraZeneca’s Innovative Medicines and EarlyDevelopment (IMED) Biotech Unit has appointed Professor Maria Belvisi as Vice President and Head of Respiratory,
NeuroVive Pharmaceutical has appointed Mark Farmery as Vice President Business Development. Dr Farmery will report to CEO Erik Kinnman and
Symcel Sweden has announced the appointment of Jesper Ericsson as new Chief Executive Officer – succeeding Christer Wallin who is
Werner Van den Eynde, MD, a specialist physician in pharmaceutical medicine, has joined NDA Group to head-up the NDA Advisory
Dignitana announces that Board Member Magnus Nilsson will resign from his position due to changes in his current professional responsibilities.
OxThera has appointed Matthew Gantz as their new CEO. He succeeds Elisabeth Lindner as CEO, who will continue as COO of Oxthera overseeing
Nordic Nanovector has appointed Dr. Reza Safaei, MD as Head of Medical Affairs. Dr. Safaei will lead the development and
